Please login to the form below

Not currently logged in
Email:
Password:

Novartis’ Peter Maag appointed president and CEO of XDx

Joins following launch of AlloMap test for transplant patients

Dr Peter Maag has left his role as president Novartis Diagnostics to join US molecular diagnostics company XDx as president and CEO.

Dr Maag spent 11 years at Novartis, including spells as head of its operations in both South Korea and Germany, and now finds himself leading a company that has recently launched one its key products – the non-invasive AlloMap test to help doctors identify whether a heart transplant has been rejected.

“Peter brings to XDx a unique combination of diagnostics and pharmaceutical experience in diverse areas of medicine,” said Michael Goldberg, chair of XDx.

“Based on his successful track record we believe Peter is uniquely qualified to lead XDx in the execution of its core strategy, including accelerating sales and geographic reach of the company's lead asset, AlloMap.”

This track record includes helping drive growth in Novartis' blood screening business, which now screens 80 per cent of the US and 30 per cent of the global blood supply.

He also created the strategy for Novartis Diagnostics' $150m investment to develop novel diagnostic solutions in transplantation, infectious diseases and prenatal care, and oversaw the launch of 10 new products in Germany.

This experience will also help him in other aspects of his mandate at XDx, which include expanding the company's pipeline and working with the management team to seek additional corporate partnerships.

3rd October 2012

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....